The cancer diagnostics company has gone into a trading halt following an adverse decision on reimbursement of its US bladder tests.
NZX-listed company will take 50% for $3.3m, and help Spectrum’s senior management fund the rest.
Sale agreement fizzles out after Hong Kong-based 'conglomerate' misses payment deadlines.
Warehouse chair says the scheme of arrangement proposal didn’t have the critical shareholder backing it needs to proceed.
The retailer reported an interim sales update ahead of formal results next month.
Investment firm initiates coverage of listed insurer with overweight rating, $1.46 price target.
A possible sell-down of Fletcher Building’s $1b land assets, subject of speculation in Australian media, is seen as a way to boost its balance sheet.
Problems with alternative jet fuel availability and the inability to upgrade its fleet effectively have hindered the airline’s science-based carbon reduction goals.
NZX-listed recruitment firm’s stock up 51% in 14 days, but says it has complied with continuous disclosure rules.
Unaudited figures for the NZX-listed honey company have come in below expectations.